Intravenous clomipramine challenge in obsessive-compulsive disorder: Predicting response to oral therapy at eight weeks

Biological Psychiatry

Volumn 44, Issue 3, 1998, Pages 220-227

  Sallee, Floyd R ^a   Koran, Lorrin M ^b   Pallanti, Stefano ^c   Carson, Stanley W ^d   Sethuraman, Gopalan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Psichiatria P   (Italy)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Clomipramine; Intravenous; OCD

Indexed keywords

CLOMIPRAMINE; GROWTH HORMONE; HYDROCORTISONE; NEUROHORMONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSPHORIA; FEMALE; HORMONE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFFECT; CLOMIPRAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0032146741     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00373-9     Document Type: Article

References (38)

1. Anderson I.M., Ware J., Daroza Davis J.M., Cowen P.J. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry. 160:1992;372-378.
2. Bastani B., Nash J.F., Meltzer H.Y. Prolactin and cortisol responses to MK212, a serotonin agonist in obsessive compulsive disorder. Arch Gen Psychiatry. 47:1990;833-837.
3. Benkelfat C., Murphy D.L., Zohar J., et al. Clomipramine in obsessive-compulsive disorder further evidence for a serotonergic mechanism of action . Arch Gen Psychiatry. 46:1989;23-28.
4. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 45:1988;177-185.
5. Coiro V., Vescovi P.P. Alcoholism abolishes the growth hormone response to sumatriptan administration in man. Metabolism. 44:1995;1577-1580.
6. George D.T., Nutt D.J., Rawlings R.R., Phillips M., Eckardt M.J., Potter W.Z., et al. Behavioral and endocrine responses to clomipramine in panic disorder patients with and without alcoholism. Biol Psychiatry. 37:1995;112-119.
7. Golden R.N., Hsiao J., Lane E., Hicks R., Rogers S., Potter W.Z. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab. 68:1989;632.
8. Golden R.N., Hsiao J., Lane E., Ekstrom R.D., Rogers S., Hicks R., et al. Abnormal neuroendocrine responsivity to acute intravenous clomipramine challenge in depressed patients. Psychiatry Res. 31:1990;39-47.
9. Golden R.N., Ekstrom D., Brown T.B., Ruegg R., Evans D.L., Haggerty J. Jr, et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry. 149:1992;1168-1175.
10. Golden RN, Bebchuk JM, Ekstrom D, Durr AL, Nicholas LM, Golding M, Mason GA. The Role of 5-HT1A Receptors in the Neuroendocrine Response to Intravenous Clomipramine Challenge. Presented at the Annual Meeting of the ACNP in San Juan, Puerto Rico. December 1995.
11. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R., Hill C., et al. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part I development, use, and reliability . Arch Gen Psychiatry. 46:1989;1006-100011.
12. Goodman W.K., McDougle C.J., Price L.H., Barr L.C., Hills O.F., Caplik J.F., et al. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder Absence of symptom exacerbation . Biol Psychiatry. 38:1995;138-149.
13. Hewlett W.A., Vinogradov S., Martin K., Berman S., Csernansky J.G. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Res. 42:1992;81-92.
14. Hollander E., Fay M., Cohen B., Campeas R., Gorman J.M., Liebowitz M.R. Serotonergic and noradrenergic responsivity in obsessive-compulsive disorder behavioral findings . Am J Psychiatry. 145:1988;1015-1017.
15. Hollander E., DeCaria C.M., Nitescu A., et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 49:1992;21-28.
16. Koran L.M., Sallee F.R., Pallanti S. Intravenous pulse loading of clomipramine produces rapid benefit in obsessive-compulsive disorder. Am J Psychiatry. 155:1997;396-401.
17. Laakmann G., Gugath M., Kuss H.J., Zygan K. Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Psychopharmacology. 82:1984;62-67.
18. Laakmann G., Wittman M., Gugath M., Muller O.A., Treusch J., Wahlster U., et al. Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride, and diazepam) on the human HPA axis. Psychopharmacology. 84:1984;66-70.
19. Lesch K.P., Hoh A., Disselkamp-Tietze J., Wiesmann M., Osterheider M., Schulte H.M. 5-hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder Comparison of patients and controls . Arch Gen Psychiatry. 48:1991;540-547.
20. Lesch K.P., Hoh A., Schulte H.M., Osterheider M., Muller T. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology. 105:1991;415-420.
21. Lopez-Ibor JJ, Lopez-Ibor I, Crespo B, Cabranes JA, Encinas M. Serotonergic Function in Obsessive-compulsive Disorder in Relation to the Comorbidity. A Study with the Clomipramine Challenge Test. Presented at the First International Conference on Education in OCD. Barcelona, Spain. June 22-25, 1995.
22. Lucey J.V., O'Keane V., Butcher G., Clare A.W., Dinan T.G. Cortisol and prolactin responses to D-fenfluramine in non-depressed patients with obsessive-compulsive disorder A comparison with depressed and healthy controls . Br J Psychiatry. 161:1992;517-521.
23. McBride P.A., DeMeo M.D., Sweeney J.A., et al. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist DL-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatry. 31:1992;19-34.
24. Mota A., Bento A., Penalva A., Pombo M., Dieguez C. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion. J Clin Endocrinol Metab. 80:1995;1973-1977.
25. Mundo E., Bellodi L., Smeraldi E. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol Psychiatry. 38:1995;525-531.
26. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression Focus on the serotonin transporter . Clin Chem. 40:1994;288-295.
27. Pigott T.A., Zohar J., Hill J.L., et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 29:1991;418-426.
28. Pigott T.A., Hill J.L., Grady T.A., et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and effect of metergoline prior to IV mCPP. Biol Psychiatry. 33:1993;3-14.
29. Pollack B.G., Perel J.M., Nathan S., Kupfer D.J. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry. 46:1989;29-35.
30. Price L.H., Goddard A.W., Barr L.C., Goodman W.K. Pharmacological challenges in anxiety disorders. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1311-1323 Raven Press, New York.
31. Richelson E. The pharmacology of antidepressants at the synapse Focus on newer compounds . J Clin Psychiatry. 55:1994;34-39.
32. Spitzer T.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R patient version 1.0 (SCID-P). 1990;APA Press, Washington.
33. Tancer M, Nicholas L, Naftolowitz D, Bebchuk J, Heine A, Golden R (1996): Comparison of Clomipramine Versus Fenfluramine Challenges. Presented at the Tenth World Congress of Psychiatry in Madrid, Spain. August 26, 1996.
34. Waeber C., Schoeffter P., Hoyer D., Palacios J.M. The serotonin 5-HT1D receptor A progress review . Neurochem Res. 15:1990;567-582.
35. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 44:1987;946-951.
36. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill H.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry. 45:1988;167-172.
37. Zohar J., Kindler S. Serotonergic probes in obsessive-compulsive disorder. Int Clin Psychopharmacology. 7:(suppl 1):1992;39-40.
38. Zohar J. Which Neurotransmitters/Neuropeptides are Involved in OCD? Presented at the 2nd International Obsessive-Compulsive Disorder Conference in Sanit-Francois, Guadeloupe, February 16-17, 1996.